Dynamic Advisor Solutions LLC Has $2.11 Million Position in Novo Nordisk A/S (NYSE:NVO)

Dynamic Advisor Solutions LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 10.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 24,480 shares of the company’s stock after selling 2,757 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Novo Nordisk A/S were worth $2,106,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Xponance Inc. raised its stake in Novo Nordisk A/S by 27.6% in the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after purchasing an additional 576 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares during the period. Daymark Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 15.9% during the 2nd quarter. Daymark Wealth Partners LLC now owns 6,290 shares of the company’s stock worth $898,000 after acquiring an additional 864 shares in the last quarter. Maverick Capital Ltd. increased its stake in Novo Nordisk A/S by 272.9% in the second quarter. Maverick Capital Ltd. now owns 7,849 shares of the company’s stock valued at $1,120,000 after acquiring an additional 5,744 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Novo Nordisk A/S by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after purchasing an additional 2,817 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NVO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Up 8.4 %

Shares of NYSE NVO opened at $87.94 on Friday. The company has a 50 day simple moving average of $95.35 and a 200 day simple moving average of $115.17. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm has a market cap of $394.65 billion, a PE ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.